The treatment of hemophilia A has progressed amazingly in recent years. Emicizumab, a bispecific-humanized monoclonal antibody, is able to improve coagulation by bridging activated factor IX and factor X. Emicizumab is administered subcutaneously and much less often compared to factor VIII products. It has low immunogenicity, does not require dose adjustment, and can be administered regardless of the presence of factor VIII inhibitors. Thrombin generation assays but not factor VIII activity are indicated to guide and monitor the treatment. Emicizumab has enabled the conversion of patients with severe forms into patients with milder forms of hemophilia A. It has reduced the number of bleeding episodes compared to both on-demand and prophylactic substitution therapy and has an excellent safety profile. Gene therapy can elevate factor VIII plasma levels for many years after a single treatment course, could offer long-term protection from bleeding episodes, and minimize or eliminate the need for substitutive treatment with factor VIII concentrates. Gene therapy can provoke an immune response, manifested by an increase in common liver enzymes, that require immunotherapy. Long term monitoring is necessary to identify possible adverse effects. Future objectives are: the development of an ideal viral vector, the possibility of its re-administration, the use of gene therapy in hemophiliac children, and determining whether it can be successfully used to induce immune tolerance to factor VIII ceteri paribus. The future will determine the place of each type of treatment and group of patients for which it is indicated.

Faculty of Medicine Lucian Blaga University of Sibiu Romania

000      

00000naa a2200000 a 4500

001      

bmc23002206

003      

CZ-PrNML

005      

20230517134552.0

007      

ta

008      

230406s2023 xr f 000 0|eng||

009      

AR

024    7_

$a 10.5507/bp.2022.046 $2 doi

035    __

$a (PubMed)36413008

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xr

100    1_

$a Mihaila, Romeo Gabriel $u Faculty of Medicine, "Lucian Blaga" University of Sibiu, Romania

245    10

$a From a bispecific monoclonal antibody to gene therapy: A new era in the treatment of hemophilia A / $c RG. Mihaila

520    9_

$a The treatment of hemophilia A has progressed amazingly in recent years. Emicizumab, a bispecific-humanized monoclonal antibody, is able to improve coagulation by bridging activated factor IX and factor X. Emicizumab is administered subcutaneously and much less often compared to factor VIII products. It has low immunogenicity, does not require dose adjustment, and can be administered regardless of the presence of factor VIII inhibitors. Thrombin generation assays but not factor VIII activity are indicated to guide and monitor the treatment. Emicizumab has enabled the conversion of patients with severe forms into patients with milder forms of hemophilia A. It has reduced the number of bleeding episodes compared to both on-demand and prophylactic substitution therapy and has an excellent safety profile. Gene therapy can elevate factor VIII plasma levels for many years after a single treatment course, could offer long-term protection from bleeding episodes, and minimize or eliminate the need for substitutive treatment with factor VIII concentrates. Gene therapy can provoke an immune response, manifested by an increase in common liver enzymes, that require immunotherapy. Long term monitoring is necessary to identify possible adverse effects. Future objectives are: the development of an ideal viral vector, the possibility of its re-administration, the use of gene therapy in hemophiliac children, and determining whether it can be successfully used to induce immune tolerance to factor VIII ceteri paribus. The future will determine the place of each type of treatment and group of patients for which it is indicated.

650    _2

$a dítě $7 D002648

650    _2

$a lidé $7 D006801

650    12

$a hemofilie A $x farmakoterapie $7 D006467

650    _2

$a faktor X $x terapeutické užití $7 D005170

650    _2

$a genetická terapie $7 D015316

655    _2

$a časopisecké články $7 D016428

655    _2

$a přehledy $7 D016454

773    0_

$w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia $x 1804-7521 $g Roč. 167, č. 1 (2023), s. 1-8

856    41

$u https://pubmed.ncbi.nlm.nih.gov/36413008 $y Pubmed

910    __

$a ABA008 $b A 1502 $c 958 $y p $z 0

990    __

$a 20230406 $b ABA008

991    __

$a 20230517134548 $b ABA008

999    __

$a ok $b bmc $g 1933534 $s 1188412

BAS    __

$a 3

BAS    __

$a PreBMC-MEDLINE

BMC    __

$a 2023 $b 167 $c 1 $d 1-8 $e 20221116 $i 1804-7521 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606

LZP    __

$b NLK198 $a Pubmed-20230406